默认为title标签的值，后台可管理

We have dedicated in vitro ADME teams for experiments and analysis, each offering first-class capabilities, high-throughput, and rapid, high-quality data delivery. The standard ADME assays are validated to ensure the accuracy and reliability of our experimental data.

Offering rodent and large animal (non-rodent) PK studies, our protocols are designed specifically to fulfill client's needs and experiment purposes, including formulation screening, dose and sampling time point setting, administration route, and surgical models.

We provide comprehensive MetID services, including preclinical in vitro and in vivo MetID, clinical human MetID (FIH, SAD, and MAD) and metabolites in safety testing (MIST) study, and metabolite biosynthesis and structural characterization.

The radiolabeled in vivo ADME studies in WuXi AppTec DMPK include radiolabeled compound synthesis, [¹⁴C] and [³H] -labeled compound preclinical in vivo ADME (rat/mouse/dog/monkey/mini-pig), radiolabeled MetID, and human AME study service.

With an experienced professional analysis team, advanced analytical instruments, whole-process digital management, and reliable quality control systems, we continuously empower our customers with high-efficiency and high-quality bioanalytical services from screening to clinical, including large and small molecule drugs, biomarkers, immunogenicity, and cell-based assays.

Through extensive experience in novel drug modalities, we have accumulated comprehensive solutions and methodologies for different drug modalities including peptides, ADCs, PDCs, antibodies, oligonucleotides, mRNAs, PROTACs, and other drug molecules.

We have set up specialized research teams mastering difficult experimental techniques to develop targeted research strategies in the areas of ophthalmic, transdermal, respiratory, neurosciences, anti-tumor, and anti-infection.

Our featured solutions include compound management service, metabolite biosynthesis and structural characterization, radiolabeled compound synthesis, and high-throughput automation platforms.